NEXGEL, Inc. (NASDAQ:NXGL) CEO Sells $14,560.00 in Stock

NEXGEL, Inc. (NASDAQ:NXGL) CEO Adam R. Levy sold 4,000 shares of the firm’s stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $3.64, for a total value of $14,560.00. Following the transaction, the chief executive officer now owns 378,284 shares in the company, valued at $1,376,953.76. This represents a 1.05 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

NEXGEL Stock Down 3.7 %

NXGL stock opened at $3.38 on Friday. The business has a 50 day simple moving average of $3.86 and a 200-day simple moving average of $3.20. NEXGEL, Inc. has a twelve month low of $1.84 and a twelve month high of $5.10. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.51 and a quick ratio of 0.93.

Institutional Inflows and Outflows

An institutional investor recently raised its position in NEXGEL stock. Northeast Financial Group Inc. increased its stake in shares of NEXGEL, Inc. (NASDAQ:NXGL) by 168.8% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 31,848 shares of the company’s stock after buying an additional 20,000 shares during the quarter. Northeast Financial Group Inc. owned about 0.50% of NEXGEL worth $82,000 at the end of the most recent quarter. 2.21% of the stock is owned by institutional investors.

About NEXGEL

NEXGEL, Inc manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was formerly known as AquaMed Technologies, Inc and changed its name to NEXGEL, Inc in November 2019.